Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?
Tx PMW ER+/HER2-neg, asymptomatic mets after 3 years adj AI?
What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, higher-volume metastases after receiving adjuvant anastrozole for 3 years?
Tx PMW ER+/HER2-neg, asymptomatic mets after 1 year adj AI?
Tx PMW ER+/HER2-neg, asymptomatic mets after 1 year adj AI?
What would you generally recommend for a postmenopausal patient with ER-positive/HER2-negative disease with asymptomatic, low-volume metastases after receiving adjuvant anastrozole for 1 year?
COCB13/3
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.
OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.